Arthritis & Rheumatism · 2011 · 128 citations · 35 references
MedicineCardiologyInternal MedicineHemodynamic ManagementPulmonary Function TestingPulmonologyPulmonary HypertensionRespiratory DiseaseKaplan-meier Survival EstimatesPulmonary Hypertension In Scleroderma
OBJECTIVE: Precapillary pulmonary hypertension (PH) is an important cause of death in patients with systemic sclerosis (SSc). It can occur in isolation (pulmonary arterial hypertension [PAH]) or in association with interstitial lung disease (ILD). Importantly, the outcomes and efficacy of PAH therapies in patients with SSc-related PH complicating ILD (PH-ILD) remain unknown. This study was undertaken to evaluate our experience with PH-ILD with regard to the efficacy and safety of PAH therapies in this patient cohort. METHODS: We conducted a retrospective analysis of consecutive SSc patients from 2 large referral centers who had PH-ILD confirmed by right-sided heart catheterization and who received targeted PAH therapies. World Health Organization (WHO) functional class, 6-minute walk distance, and hemodynamic parameters were assessed at baseline and after a mean ± SD of 7.7 ± 6.2 months of treatment for PAH. Kaplan-Meier and Cox proportional hazards models were used to analyze survival and to identify prognostic factors. RESULTS: Seventy patients were included in the study. No significant changes were observed in WHO functional class, 6-minute walk distance, or hemodynamic parameters after therapy. The 1-, 2-, and 3-year survival estimates were 71%, 39%, and 21%, respectively. In the multivariate model, worsening oxygenation during followup and reduced renal function were the only significant risk factors for death. CONCLUSION: This study represents the largest series to date in which the impact of PAH therapies in SSc-related PH-ILD was examined. In this cohort, PAH therapies were associated with no clear benefits. Deterioration in oxygenation was an important determinant of long-term survival. Prospective clinical trials focusing on this group of patients are warranted.
35
Inhaled Iloprost for Severe Pulmonary Hypertension
Horst Olschewski, Gérald Simonneau, Nazzareno Galiè et al. · New England Journal of Medicine · 2002 · 1.8K citations · Full text
Cyclophosphamide versus Placebo in Scleroderma Lung Disease
Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text
Predicting Survival in Pulmonary Arterial Hypertension
Raymond L. Benza, Dave P. Miller, Mardi Gomberg‐Maitland et al. · Circulation · 2010 · 1.6K citations · Full text